Posted inClinical Updates Neurology news
Selective D1/D5 Receptor Agonism in Parkinson Disease: Insights from the TEMPO-3 Phase 3 Trial of Tavapadon
The Phase 3 TEMPO-3 trial demonstrates that tavapadon, a novel selective D1/D5 agonist, significantly improves daily 'good-on-time' and reduces 'off-time' in Parkinson’s disease patients with motor fluctuations, presenting a potential shift in adjunctive therapy.